ARX vs RYAN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

RYAN is the larger of the two ($11.94B market cap): the incumbent the market prices for continued execution (19.38x forward earnings, beta 0.54). ARX is the smaller challenger ($4.32B), priced similarly on forward earnings (21.22x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ARX vs RYAN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricARXRYANWhat it tells you
Market cap$4.32B$11.94BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E21.2219.38Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range100% of range60% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book6.0112.69How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ARX and RYAN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARX and RYAN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARX and RYAN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Accelerant Holdings (ARX) do?

Accelerant Holdings operates a data-driven risk exchange for specialty insurance. On one side are managing general agents (MGAs), the specialist underwriters who design and sell niche insurance products; on the other are risk capital partners such as insurers, reinsurers, and institutional investors who put up the capital to back those policies. Accelerant sits in the middle, using proprietary technology, data, and machine learning to match risk with capital, share high-fidelity underwriting data, and monitor portfolios. It earns a fixed-percentage, volume-based fee for sourcing, managing, and monitoring the business written through the exchange, which spans more than 500 specialty insurance products across 22 countries. The company reports through three segments: Exchange Services, MGA Operations, and Underwriting, and describes its model as capital-light because it aims to retain only a small share of the premium risk (roughly 9% in 2025) and pass the rest to third-party capital.

Full ARX guide

What does Ryan Specialty Holdings (RYAN) do?

Ryan Specialty Holdings is an international specialty insurance intermediary founded by Patrick Ryan (who also founded Aon). It sits between retail insurance brokers and carriers, operating two core engines: wholesale brokerage (led by RT Specialty, one of the largest E&S and binding-authority platforms in the US) and underwriting management, where its managing general underwriters (MGUs) hold delegated authority from carriers to underwrite niche risks in areas like energy, healthcare, construction, and enterprise risk. It does not take underwriting risk on its own balance sheet; it earns commissions and fees for placing and structuring hard-to-place specialty coverage.

Full RYAN guide

ARX vs RYAN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ARX drivers: The Thoma Bravo deal sets the price; Go-shop ended with no rival bid.
  • RYAN drivers: E&S market tailwind; Delegated underwriting (MGU) mix.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: With a signed all-cash agreement, the main risk is deal completion. For RYAN, the biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth.

ARX or RYAN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARX if you believe its drivers more; RYAN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARX and RYAN guides.

ARX vs RYAN: the full fundamentals

ARX. Since August 13, 2026 ARX has been valued by the Thoma Bravo offer, not by earnings multiples. At $19.75 the shares trade about 2.5% below the $20.25 cash price, a spread that reflects the time until the expected first-half 2027 close and the chance the deal does not complete. Measures such as about 4 times TTM sales or 21 times forward earnings describe what the buyer is paying rather than where the stock is likely to trade before closing.

RYAN. At $40.19 on October 16, 2026, Ryan Specialty trades at about 57 times trailing reported earnings but only about 16 times forward earnings and about 10 times EV/EBITDA, cheaper than in July after a roughly 21% YTD decline. The gap between trailing and forward multiples reflects acquisition amortization and interest that hold down reported profit. Q3 results on October 29, 2026 will show whether organic growth is holding as property rates soften.

Headline figures (approximate, October 2026): ARX shows deal price (thoma bravo, all cash) $20.25 per share; enterprise value >$4 billion, share price / spread to deal $19.75 (Oct 16, 2026) / ~2.5%, expected close First half of 2027, revenue (ttm) ~$1.07 billion; RYAN shows revenue (ttm) ~$3.2B, q2 2026 revenue ~$917M (up ~7% YoY), operating margin (ttm) ~25%, net income (ttm) ~$99M.

The bottom line: ARX vs RYAN

ARX and RYAN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARX and RYAN exposure against your real portfolio. It is not an investment adviser.

Wondering how ARX or RYAN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Accelerant Holdings

Ask Walnut's AI anything about ARX and see how it fits what you own.

FAQ

What is the difference between ARX and RYAN?

+

Accelerant Holdings operates a data-driven risk exchange for specialty insurance. Ryan Specialty Holdings is an international specialty insurance intermediary founded by Patrick Ryan (who also founded Aon). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ARX or RYAN the better stock?

+

Neither is universally better. RYAN is the larger incumbent; ARX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ARX or RYAN?

+

On forward P/E (as of November 2026), ARX trades at 21.22x and RYAN at 19.38x, so RYAN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ARX and RYAN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ARX vs RYAN?

+

ARX: With a signed all-cash agreement, the main risk is deal completion. Shareholder approval, regulatory approvals for an insurance business, financing and other conditions could delay or block the transaction, and the expected close in the first half of 2027 leaves months for something to change. If the deal failed, the stock would likely fall back toward a price set by fundamentals; it traded near $13 in July 2026, before the announcement-day jump of about 43%. The upside is capped near $20.25 unless a higher bid appears, and the go-shop ended without one. Holders also bear the time value of waiting: a roughly 2.5% spread over several months is a modest return for that risk. The underlying business risks still apply to a broken-deal scenario: a capital-light model unproven across a full insurance cycle, dependence on keeping MGAs and capital partners engaged, a large reported net loss tied to the IPO, and cyclical specialty insurance pricing. RYAN: The biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth. Softer rates directly reduce commission-based revenue, and Q2 2026 revenue growth already slowed to about 7%. Reported profit is thin, with trailing net income of about $99 million (a 3% profit margin) because of amortization, interest, and acquisition-related costs, so the trailing P/E sits near 57x. Acquisition-heavy growth brings integration, goodwill, and leverage risk, and the company carries about $3.8 billion of debt. Analysts have been trimming price targets into the Q3 report. Finally, it depends on relationships with carriers for delegated underwriting capacity, which can tighten in a downturn, and it operates in a competitive field against larger and well-capitalized wholesalers.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ARX or RYAN; figures are approximate and dated (as of November 2026). Verify current data before investing.